Innovations In API Manufacturing Of Small Molecule Drugs

By Dirk-Jan van Zoelen, Ph.D., Business Unit Director API, Oss, The Netherlands

Small‑molecule API manufacturing is under pressure from rising development costs, workforce constraints, stricter regulations, and growing sustainability expectations. Progress depends on coordinated innovation across the entire manufacturing lifecycle. Automation and robotics are reducing repetitive tasks and accelerating process optimization, while emerging synthetic approaches—such as photochemistry, electrochemistry, and biocatalysis—enable shorter, more efficient routes to complex molecules.

Advances in continuous processing and process intensification help overcome scale‑up limitations, safety risks, and energy inefficiencies. Shifts in therapeutic focus, including highly potent compounds, targeted conjugates, and protein degradation strategies, introduce new challenges that demand stronger analytical control and risk‑based decision making. Developments in analytical science, including data‑driven tools and artificial intelligence, improve impurity detection and process understanding. Environmental responsibility is addressed through practical examples that reduce solvent use and avoid persistent chemicals. Together, these innovations show how API manufacturing is evolving toward greater efficiency, resilience, and long‑term sustainability.